Abstract
Background Epidemiological studies have shown increased comorbidity between depression and autoimmune diseases. The mechanisms driving the comorbidity are poorly understood, and a highly powered investigation is needed to understand the relative importance of shared genetic influences. We investigated the evidence for pleiotropy from shared genetic risk alleles between these traits in the UK Biobank (UKB).
Methods We defined autoimmune and depression cases using information from hospital episode statistics, self-reported conditions and medications, and mental health questionnaires. Pairwise comparisons of depression prevalence between autoimmune cases and controls, and vice-versa, were performed. Cross-trait polygenic risk score (PRS) analyses were performed to test for pleiotropy, i.e. testing whether PRS for depression could predict autoimmune disease status, and vice-versa.
Results We identified 28k cases of autoimmune diseases (pooling across 14 traits) and 324k autoimmune controls, and 65k cases of depression and 232k depression controls. The prevalence of depression was significantly higher in autoimmune cases compared to controls, and vice-versa. PRS for myasthenia gravis and psoriasis were significantly higher in depression cases compared to controls (p < 5.2×10−5, R2 <= 0.04%). PRS for depression were significantly higher in inflammatory bowel disease, psoriasis, psoriatic arthritis, rheumatoid arthritis and type 1 diabetes cases compared to controls (p < 5.8×10−5, R2 range 0.06% to 0.27%), and lower in coeliac disease cases compared to controls (p < 5.4×10−7, R2 range 0.11% to 0.15%).
Conclusions Consistent with the literature, depression was more common in individuals with autoimmune diseases compared to controls, and vice-versa, in the UKB. PRS showed some evidence for involvement of shared genetic factors, but the modest R2 values suggest that shared genetic architecture accounts for only a small proportion of the increased risk across traits.
Competing Interest Statement
CML is a member of the SAB for Myriad Neuroscience. The remaining authors declare no competing interests.
Funding Statement
This work was supported by the UK Medical Research Council (PhD studentship to KPG; grant MR/N015746/1). This paper represents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UKB received ethical approval from the North West - Haydock Research Ethics Committee (reference 16/NW/0274). This study was conducted under application number 18177. The MDD GWAS summary statistics results from 23andMe were available through a Data Transfer Agreement between 23andMe, Inc., and King's College, London. Only summary statistics were shared with no individual level data. 23andMe participants provided informed consent and participated in the research online. The 23andMe protocol was approved by an external Association for the Accreditation of Human Research Protection Programs accredited Institutional Review Board, Ethical and Independent Review Services. Participants were included in the analysis on the basis of consent status as checked at the time data analyses were initiated.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Minor revisions to the main paper and supplementary materials
Data Availability
Available from UK Biobank subject to standard procedures (www.ukbiobank.ac.uk). The full GWAS summary statistics for the 23andMe discovery data set will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Please visit https://research.23andme.com/collaborate/#publication for more information and to apply to access the data.
